President Trump’s groundbreaking deals with pharmaceutical giants are already delivering lower prescription drug prices for Americans, as Eli Lilly slashes the cost of its Zepbound weight-loss medication by up to $200 per month.
Story Highlights
- Eli Lilly cuts Zepbound vial prices up to $200 monthly following Trump’s pharmaceutical deals.
- Starting dose now $299 per month, down from $349 on the company’s direct platform.
- Trump’s agreements introduce the first-ever Medicare coverage for obesity drugs and a new TrumpRx website.
- Price reductions come ahead of Trump’s January launch of the government’s direct-to-consumer drug site.
Trump Administration Delivers on Drug Price Promises
Eli Lilly announced that it is reducing cash prices for Zepbound weight-loss drug vials on its LillyDirect platform, marking a tangible result of President Trump’s recent pharmaceutical agreements.
The price cuts range from $50 to $200 per month across different dosages, demonstrating how Trump’s pro-business negotiations are benefiting everyday Americans. This move builds directly on Trump’s deals with major drug manufacturers to expand access and affordability for critical medications.
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site https://t.co/O2YC19niR4
— Biotech Nerdy (@biotechnerdy) December 1, 2025
Significant Monthly Savings for Cash-Paying Patients
Starting December 1, patients can access Zepbound’s starting dose for $299 per month, down from $349. The 5-milligram dose drops to $399 per month, while higher doses remain at $449 per month, down from $499.
These reductions represent substantial savings compared to Zepbound’s list price of approximately $1,086 per month, addressing a major affordability barrier that has prevented many Americans from accessing this treatment.
Strategic Timing Ahead of TrumpRx Launch
Eli Lilly’s announcement strategically precedes the January launch of TrumpRx, Trump’s new government direct-to-consumer pharmaceutical website.
While Trump’s formal agreement with Eli Lilly focuses on multi-dose pen versions pending FDA approval, this immediate price reduction on existing vials allows patients to access affordable treatment more quickly.
The timing demonstrates pharmaceutical companies’ responsiveness to Trump’s market-based approach to healthcare reform, prioritizing patient access over bureaucratic delays.
Market Competition Drives Further Price Reductions
The announcement follows rival Novo Nordisk’s recent price cuts for Wegovy and Ozempic, reducing the monthly cost to $349 from $499 for existing patients. Novo Nordisk also introduced a $199 monthly introductory rate for new patients’ first two months.
This competitive dynamic, encouraged by Trump’s pharmaceutical partnerships, creates a market-driven solution to drug affordability that benefits consumers without heavy-handed government intervention.
Direct-to-consumer sales now represent over one-third of new Zepbound prescriptions, highlighting patients’ preference for market-based access options.
